Latest Corporate News
Fifth Third Completes Merger with Comerica, Becomes 9th Largest U.S. Bank
Fifth Third Bancorp closed its merger with Comerica, creating a bank with $294 billion in assets and operations in high-growth markets. The deal enhances retail banking, digital capabilities, and commercial payments, with plans for 1,750 branches by 2030.
CEO Tim Spence highlighted opportunities in scaling middle market expertise and expanding retail presence.
Netflix Announces $82.7 Billion Acquisition of Warner Bros. Discovery
Netflix revealed a massive $82.7 billion deal to acquire Warner Bros. Discovery, marking one of the year's biggest M&A transactions. Terms were updated in January amid rising corporate optimism for dealmaking.
The acquisition reflects proactive growth strategies leveraging technology and scale.
Global Payments Completes $24.25 Billion Bid for Worldpay
Global Payments finalized its $24.25 billion acquisition of Worldpay, boosting its position in payments processing. This deal contributes to the early 2026 surge in M&A activity.
Surveys show 62% of U.S. CEOs planning active pursuit of deals.
Boston Scientific Plans $14.5 Billion Purchase of Penumbra
Boston Scientific announced a $14.5 billion deal for Penumbra, kicking off strong M&A in medtech. The acquisition expands its portfolio amid high demand for devices.
It aligns with January's wave of corporate consolidations.
Oracle Expects to Raise Up to $50 Billion for Cloud Expansion in 2026
Oracle plans to raise approximately $50 billion in gross cash this year, half through funding combinations, to fuel its cloud push. This supports aggressive infrastructure investments amid AI growth.
The announcement came amid volatile Asia-Pacific markets.
AbbVie Partners with RemeGen on $5.6 Billion PD-1/VEGF Deal
AbbVie secured global ex-China rights to RemeGen's RC148 therapy for about $5.6 billion during JPM 2026. The partnership targets oncology with a bispecific antibody.
It underscores surging pharma BD&M&A over $50 billion in January.
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion
Lilly bought clinical-stage biotech Ventyx for $1.2 billion in an all-cash deal focused on inflammatory diseases. The acquisition is set to close in H1 2026.
It highlights big pharma's interest in autoimmune therapies.
Alphabet and Amazon Set to Report Earnings Amid AI Scrutiny
Alphabet and Amazon earnings are highlights this week, with focus on cloud growth and AI infrastructure. Investors watch for updates on data center demand and spending plans.
Pharma giants like Eli Lilly and Novo Nordisk also report.
M&A Activity Expected to Surge in 2026 with AI Driving Deals
Global M&A rose 40% to $4.9 trillion in 2025; 80% of executives expect sustained or increased activity. AI adoption accelerates competitive advantages in dealmaking.
U.S. CEOs show 62% intent to pursue deals, up from 35%.
Charles River Laboratories Acquires Cambodia's K.F. Ltd.
Charles River Labs bought K.F. Ltd., enhancing its preclinical services in Asia. The deal is part of January's robust M&A in biotech and labs.
It supports global expansion amid research demands.
Recordati Licenses Moderna's mRNA Therapy for Up to $160 Million
Recordati gained global rights to Moderna's mRNA-3927 for propionic acidemia, worth up to $160 million. Moderna leads clinical development in collaboration.
This fits the $50 billion+ pharma M&A trend in January.
AstraZeneca Acquires AbelZeta's CAR-T Therapy Rights for $630 Million
AstraZeneca obtained rights to AbelZeta’s GPC3 CAR-T for solid tumors in a $630 million deal. It bolsters cell therapy strategies.
The transaction on Jan 19 reflects ongoing CAR-T interest.